XML 28 R18.htm IDEA: XBRL DOCUMENT

Royalty and other revenue	3 Months Ended
Royalty and other revenue	Mar. 31, 2023
License And Royalty Revenue [Abstract]
Royalty and other revenue	Royalty and other revenuebluebird bio has out-licensed intellectual property to various third parties. Under the terms of these agreements, some of which were assumed by the Company in connection with the separation, bluebird bio and the Company may be entitled to royalties and milestone payments. The Company recognized $1.4 million and $0.9 million of royalty and other revenue in the three months ended March 31, 2023 and 2022, respectively. Juno Therapeutics In May 2020, bluebird bio entered into a non-exclusive license agreement with Juno Therapeutics, Inc. (“Juno”), a wholly-owned subsidiary of BMS, related to lentiviral vector technology to develop and commercialize CD-19-directed CAR T cell therapies. The agreement was assumed by the Company in connection with the separation. Royalty revenue recognized from sales of lisocabtagene maraleucel is included within royalty and other revenue in the condensed consolidated statement of operations and comprehensive loss.